Provided is the use of a V2 selective vasopressin antagonist compound or a pharmaceutically acceptable salt thereof in the preparation of medicament for reducing cardiotoxicity and/or improving survival from doxorubicin chemotherapy wherein the medicament is for administering simultaneously with or prior to doxorubicin administration.